No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction

Indian Heart Journal

Volumn 68, Issue 4, 2016, Pages 539-551

  Gupta, Sanjiv ^a   Gupta, Madan Mohan ^b  

^a SDM Hospital   (India)

^b Heart and Diabetic Clinic   (India)

Author keywords

Primary percutaneous intervention; ST elevation myocardial infarction; Thrombus aspiration

Indexed keywords

ABCIXIMAB; ADENOSINE; ANTIOXIDANT; ATRIAL NATRIURETIC FACTOR; CARDIOVASCULAR AGENT; CYCLOSERINE; DILTIAZEM; ELAMIPRETIDE; ENDOTHELIN RECEPTOR ANTAGONIST; ENIPORIDE; EPINEPHRINE; EPTIFIBATIDE; EXENDIN 4; FX 06; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICARDIPINE; NICORANDIL; NITROPRUSSIDE SODIUM; PEXELIZUMAB; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TIROFIBAN; UNCLASSIFIED DRUG; VERAPAMIL;

BLEEDING; BRONCHOSPASM; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR THERAPEUTIC DEVICE; CONTRAST ECHOCARDIOGRAPHY; CORONARY ANGIOGRAPHY; CORONARY FLOW RESERVE; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; EQUIPMENT DESIGN; HEART ARRHYTHMIA; HEART BLOCK; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEREDITY; HUMAN; HYPOTENSION; INCIDENCE; INTRACORONARY DOPPLER GUIDE WIRE; ISCHEMIC POSTCONDITIONING; NO REFLOW PHENOMENON; NONHUMAN; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT; THROMBECTOMY; THROMBOEMBOLISM; THROMBUS ASPIRATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE EFFECTS; CORONARY ARTERY BLOOD FLOW; NO-REFLOW PHENOMENON; PATHOPHYSIOLOGY; ST ELEVATION MYOCARDIAL INFARCTION;

CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; HUMANS; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; ST ELEVATION MYOCARDIAL INFARCTION;

EID: 84963819387     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ihj.2016.04.006     Document Type: Review

References (122)

1. 1 O'Gara, P.T., Kushner, F.G., Ascheim, D.D., et al. 2013 ACCF/AHA guidelines for the management of ST elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61 (2013), 485–510.
2. 2 Jaffe, R., Dick, A., Strauss, B.H., Prevention and treatment of microvascular-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach. J Am Coll Cardiol Interv 3 (2010), 695–704.
3. 3 Eeckhout, E., Kern, M.J., Clinical perspective: the coronary no-reflow phenomena: a review of mechanisms and therapies. Eur Heart J 22 (2001), 729–739.
4. 4 Brosh, D., Assali, A.R., Mager, A., et al. Effect of no reflow during primary percutaneous coronary intervention for acute myocardial infarction on six month mortality. Am J Cardiol 99 (2007), 442–445.
5. 5 Morishima, I., Sone, T., Okumura, K., et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first myocardial infarction. J Am Coll Cardiol 36 (2000), 1202–1209.
6. 6 Bolognese, L., Carrabba, N., Parodi, G., et al. Impact of microvascular dysfunction on left ventricular remodelling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 109 (2004), 1121–1126.
7. 7 Ndreppa, G., Tiroch, K., Keta, D., et al. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv 3 (2010), 27–33.
8. 8 Berg, R., Buhari, C., Treating and preventing no reflow in the cardiac catheterization laboratory. Curr Cardiol Rev 8 (2012), 209–214.
9. 9 Ndreppa, G., Tiroch, K., Fusaro, M., et al. 5-Year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 55 (2010), 2383–2389.
10. 10 Galiuto, L., Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathological classification. Heart 90 (2004), 123–125.
11. 11 Harrison, R.W., Aggarwal, A., Ou, F.S., et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol 111:2 (2013), 178–184.
12. 12 Niccoli, G., Scalone, G., Lerman, A., Crea, F., Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J, 2015, 10.1093/eurheartj/ehv484.
13. 13 Hermann, J., Lerman, A., The endothelium: dysfunction and beyond. J Nucl Cardiol 8 (2001), 197–206.
14. 14 Marks, D.S., Gudapati, S., Prisant, L.M., et al. Mortality in patients with microvascular obstruction. J Clin Hypertens (Greenwich) 6 (2004), 304–309.
15. 15 Lerman, A., Homes, D.R., Herrmann, J., Gersh, B.J., Microcirculatory dysfunction in ST-elevation myocardial infarction: cause, consequence, or both?. Eur Heart J 28 (2007), 788–797.
16. 16 Kloner, R.A., Ganote, C.E., Jennings, R.B., The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Investig 54 (1974), 1496–1508.
17. 17 Bekkers, S.C., Yazdani, S.K., Virmani, R., Waltenberger, J., Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol 55:16 (2010), 1649–1660.
18. 18 Frohlich, G.M., Meier, P., White, S.K., Yellon, D.M., Hausenloy, D.J., Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J 34 (2013), 1714–1722.
19. 19 Wu, K.C., Zerhouni, E.A., Judd, R.M., et al. Prognostic significance of microvascular obstruction magnetic resonance imaging in patients with acute myocardial infarction. Circulation 97 (1998), 765–772.
20. 20 Basso, C., Rizzo, S., Thiene, G., The metamorphosis of myocardial infarction following coronary revascularization. Cardiovasc Pathol 19 (2010), 22–28.
21. 21 Yoshino, S., Ciluffo, R., Best, P.Z., et al. A single nucleotide polymorphism associated with abnormal coronary micro-vascular function. Coron Artery Dis 25 (2014), 281–289.
22. 22 Niccoli, G., Burzotta, F., Galiuto, L., Crea, F., Myocardial no-reflow in humans. J Am Coll Cardiol 54 (2009), 281–292.
23. 23 Niccoli, G., Lanza, G.A., Spaziani, C., et al. Baseline systemic inflammatory status and no-reflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction. Int J Cardiol 117:3 (2007), 306–311.
24. 24 Danesh Sani, H.D., Eshraghi, A., Sahri, B., Vejdanparast, M., No-reflow phenomenon in patients with ST-elevation acute myocardial infarction, treated with primary percutaneous coronary intervention: a study of predictive factors. J Cardiothorac Med 2:4 (2014), 221–226.
25. 25 Abdi, S., Rafizadeh, O., Peighambari, M., Basiri, H., Bakhshandeh, H., Evaluation of clinical and procedural predictive factors of no-reflow phenomenon following primary percutaneous coronary intervention. Res Cardiovasc Med, 4(2), 2005, e25414.
26. 26 Wang, J.W., Zhoud, Z.Q., Chen, Y.D., Want, C.H., Zhu, X.L., A risk score for no reflow in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention. Clin Cardiol 38:4 (2015), 208–215.
27. 27 Topark, C., Tabakci, M.M., Zimsek, Z., et al. Platelet/lymphocyte ratio was associated with impaired myocardial perfusion and both in-hospital and long-term adverse outcome in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Postep Kardiol Interwencyjnej 11:4 (2015), 288–297.
28. 28 Soeda, T., Higuma, T., Abe, N., et al. Intravascular ultrasound, but not optical coherence tomography, predicts no reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction cause by plaque rupture. J Am Coll Cardiol, 67(10S), 2015 1244-071.
29. 29 Soeda, T., Higuma, T., Abe, N., et al. Morphological predictors for no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction caused by plaque rupture. Eur Heart J Cardiovasc Imaging(January), 2016 pii:jev341 [epub ahead of print].
30. 30 Mazhar, J., Maschicharan, M., Farshid, A., Predictors and outcome of no-reflow post primary percutaneous coronary intervention for ST elevation myocardial infarction. IJC Heart Vasc 10 (2016), 8–12.
31. 31 Gibson, M.C., Cannon, C.P., Murphy, S.A., Marble, S.J., Barron, H.V., Braunwald, E., Relationship of TIMI myocardial perfusion grades, flow grades, frame count and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 105 (2002), 1909–1913.
32. 32 Hoffmann, P., Haager, P., Lepper, W., Franke, A., Hanrath, P., Relation of coronary flow pattern to myocardial blush grade in patients with first myocardial infarction. Heart 89:10 (2003), 1147–1151.
33. 33 Henriques, J.P.S., Zijlistra, F., van't Hof, A.W.J., et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation 107 (2003), 2115–2119.
34. 34 Schroder, R., Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation 110 (2004), e506–e5010.
35. 35 Sorajja, P., Gersh, B.J., Costantini, C., et al. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 26 (2005), 667–674.
36. 36 Giugliano, R.P., Sabatine, M.S., Gibson, C.M., et al. Combined assessment of thrombolysis in myocardial infarction Flow grade, myocardial perfusion grade and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am J Cardiol 93 (2004), 1362–1367.
37. 37 Iwakura, K., Ito, H., Takiuchi, S., et al. Alteration in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction. Circulation 94 (1996), 1269–1275.
38. 38 Claessen, B.E.P.M., Bax, M., Delewi, R., Meuwissen, M., Henriques, J.P.S., Piek, J.J., The Doppler flow wire in acute myocardial infarction. Heart 96 (2010), 631–635.
39. 39 Yamamuro, A., Akasaka, T., Tamita, K., et al. Coronary flow velocity pattern immediately after percutaneous coronary intervention as a predictor of complications and in-hospital survival after acute myocardial infarction. Circulation 106 (2002), 3051–3056.
40. 40 Ito, H., No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med 3:9 (2006), 499–506.
41. 41 Lepper, W., Belcik, T., Wei, K., Linder, J., Sklenar, J., Kaul, S., Myocardial contrast echocardiography. Circulation 109 (2004), 3132–3135.
42. 42 Galiuto, L., Garramone, B., Scara, A., et al. The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post infarction reperfusion in predicting left ventricular remodelling: result of the multicentre AMICI study. J Am Coll Cardiol 51 (2008), 552–559.
43. 43 Sanjeev, K., The no-reflow phenomenon following acute myocardial infarction: mechanism and treatment options. J Cardiol 64 (2014), 77–85.
44. 44 Wu, K.C., CMR of microvascular obstruction and haemorrhage in myocardial infarction. J Cardiovasc Magn Reson, 14, 2012, 68.
45. 45 van Kranenbrug, M., Magro, M., Thiele, H., et al. Prognostic value of microvascular obstruction and infarct size as measured by CMR in STEMI patients. J Am Coll Cardiol Imaging 7 (2014), 930–939.
46. 46 Burzotta, F., Trani, C., Ramagnoli, E., et al. Manual thrombus aspiration improves myocardial reperfusion: the randomized evaluation of the effect of mechanical reduction of distal embolization by thrombus aspiration in primary and rescue angioplasty (REMEDIA) trial. J Am Coll Cardiol 46 (2005), 371–376.
47. 47 Svilass, T., Vlaar, P.J., van der Horst, I.C., et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 358 (2008), 557–576.
48. 48 Vlaar, P.J., Svilass, T., van der Horst, W.C., et al. Cardiac death and reinfarction after 1 year in there thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction study (TAPAS): a 1-year follow-up study. Lancet 371:9628 (2008), 1915–1920.
49. 49 Dudek, D., Mielecki, W., Burzotta, F., et al. Thrombus aspiration followed by direct stenting: a novel strategy of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. Results of the Polish–Italian–Hungarian-Randomized ThrombEctomy (PIHRATE Trial). Am Heart J 160:5 (2010), 966–972.
50. 50 Frobert, O., Lagerqvist, B., Olivercrona, G.K., et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 369 (2013), 1587–1597.
51. 51 Jolly, S.S., Carins, J.A., Yusuf, S., et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 372:15 (2015), 1389–1398.
52. 52 Migliorini, A., Stabile, A., Rodriguez, A.E., et al. Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction. J Am Coll Cardiol 56:16 (2010), 1298–1306.
53. 53 Lefevre, T., Garcia, E., Reimers, B., et al. X-sizer for thrombectomy in acute myocardial infarction improves ST-segment resolution. J Am Cardiol 46:2 (2005), 246–252.
54. 54 Stone, G.W., Maehara, A., Witzenbichler, B., et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 307:17 (2012), 1817–1826.
55. 55 Brenner, S.J., Maehara, A., Dizon, J.M., et al. Relationship between myocardial reperfusion, infarct size and mortality; the INFUSE-AMI (intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction) trial. J Am Coll Cardiol Cardiovasc Interv 6:7 (2013), 718–724.
56. 56 Bavry, A.A., Kumbhani, D.J., Bhatt, D.J., Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. Eur Heart J 29 (2008), 2989–3001.
57. 57 Burzotta, F., De Vita, M., Gu, Y.L., et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction; an individual patient-data pooled analysis of 11 trials. Eur Heart J 30 (2009), 2193–2203.
58. 58 Mongeon, F.P., Belisle, P., Joseph, L., Eisenberg, M.J., Rinfert, S., Adjunctive thrombectomy for acute myocardial infarction: a Bayesian meta-analysis. Circ Cardiovasc Interv 3 (2010), 6–16.
59. 59 Tamhane, U.U., Chetcuti, S., Hameed, I., Grossman, P.M., Mosucci, M., Gurm, H.S., Safety and efficacy of thrombectomy in patients undergoing primary percutaneous coronary intervention for acute ST elevation MI: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord, 10, 2010, 10.
60. 60 De Luca, G., Navarese, E.P., Suryapranta, H., A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol 166:3 (2013), 606–612.
61. 61 Deng, S.B., Wang, J., Xiao, J., et al. Adjunctive manual thrombus aspiration during ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials. PLOS ONE, 9(11), 2014, e 113481, 9596123, 10.1371/journal.pone.0113481.
62. 62 Kumbhani, D.J., Bavry, A.A., Desai, M.Y., Bangalore, S., Bhatt, D.L., Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: an updated meta-analysis of randomized trials. J Am Coll Cardiol 62:16 (2013), 1409–1418.
63. 63 Jolly, S.S., Cairns, J.A., Yusuf, S., et al. Stroke in the TOTAL trial: a randomized trial of routine thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction. Eur Heart J 36 (2015), 2364–2372.
64. 64 Elgendy, I.Y., Huo, T., Bhatt, D.L., et al. Is aspiration thrombectomy beneficial in patients undergoing primary percutaneous coronary intervention? Meta-analysis of randomized trials. Circ Cardiovasc Interv, 8, 2015, e002258.
65. 65 Steg, P.G., James, S.K., Atar, D., et al. ESC guideline for the management of acute myocardial infarction in patients presenting with ST segment elevation. Eur Heart J 33:20 (2012), 2569–2619.
66. 66 Authors/Task Force Members, Windecker, S., Kolh, P., et al. ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic c Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35 (2014), 2541–2619.
67. 67 Levine, G.N., Bates, E.R., Blankenship, J.C., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation. American Heart Association Task Force on Practice Guidelines and the Society of Cardiovascular Angiography and Interventions. Circulation 124 (2011), e574–e651.
68. 68 Levine, N.G., Bates, E.R., Blankenship, J.C., et al. ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of 2011 ACCF/AHA/SCAI guidelines for percutaneous coronary intervention and 2013 ACCF/AHA guidelines for the management of ST-elevation myocardial infarction. Circulation, 2015 http://circ.ahajournals.org/content/early/2015/10/20/CIR.0000000000000336.full.pdf.
69. 69 Freixa, X., Belle, L., Joseph, L., et al. Immediate vs delayed stenting in acute myocardial infarction: a systemic review and meta-analysis. EuroIntervention 8 (2013), 1207–1216.
70. 70 Carrick, D., Oldroyd, K.G., McEntegart, M., et al. A randomized trial of deferred stenting versus immediate stenting to prevent no or slow-flow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). J Am Coll Cardiol 63 (2014), 2088–2098.
71. 71 Piscione, F., Danzi, G.B., Cassese, S., et al. Multicentre experience with MGuard net protective stent in ST-elevation myocardial infarction: safety, feasibility and impact on myocardial infarction. Catheter Cardiovasc Interv 75:5 (2010), 715–721.
72. 72 Dudek, D., Dziewierz, A., Rzeszutko, L., et al. Mesh covered stent in ST-segment elevation myocardial infarction. EuroIntervention 6:5 (2010), 582–589.
73. 73 Fernandez-Cisnal, A., Cid-Alvarez, B., Alvarez-Alvarez, B., et al. Real world comparison of the MGuard stent versus the bare metal stent for ST elevation myocardial infarction (the REWARD-MI study). Catheter Cardiovasc Interv 85:1 (2015), E1–E9.
74. 74 Stone, G.W., Abizaid, A., Silber, S., et al. Prospective, randomized, multicentre evaluation of a polyethylene terephthalat micronet mesh-covered stent (MGuard) in ST-segment myocardial infarction (The MASTER trial). J Am Coll Cardiol 60:19 (2012), 1975–1984.
75. 75 Costa, R.A., Abizaid, A., Lotan, C., et al. Impact of thrombus burden on outcomes after standard versus mesh-covered stents in acute myocardial infarction (from the MGuard for acute ST elevation reperfusion trial). Am J Cardiol 115:2 (2015), 161–166.
76. 76 Gracida, M., Ramaguera, R., Jacobi, F., Gomez-Hospital, J.A., Cequier, A., The MGuard coronary stent: safety, efficacy and clinical utility. Vasc Health Risk Manag 11 (2015), 533–539.
77. 77 Cetin, M., Kiziltunc, E., Cetin, Z.G., Kundi, H., Gulkan, B., Cicekcioglu, H., Case report: a practical method for no-reflow treatment. Hindawai, 2016, 10.1155/2016/9596123.
78. 78 Mahaffey, K.W., Puma, J.A., Barbagelata, N.A., et al. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial. J Am Coll Cardiol 34 (1999), 1711–1720.
79. 79 Ross, A.M., Gibbons, R.J., Stone, G.W., et al. A randomized, double-blinded, placebo-controlled multicentre trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD II). J Am Coll Cardiol 45 (2005), 1775–1780.
80. 80 Assali, A.R., Sdringola, S., Ghani, M., et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of no reflow phenomenon. Catheter Cardiovasc Interv 51 (2000), 27–31.
81. 81 Niccoli, G., Rigattieri, S., De Vita, M.R., et al. Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). J Am Coll Cardiol Cardiovasc Interv 6 (2013), 580–589.
82. 82 Faruk Akturk, I., Arif Yalcin, A., Biyik, I., et al. Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of no reflow phenomenon in patients with acute myocardial infarction. Minerva Cardioangiol 62:5 (2014), 389–397.
83. 83 Su, Q., Nyi, S., Li, L., Adenosine and verapamil for no reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev, 18(May (5)), 2015, CD009503.
84. 84 Gao, Q., yang, B., Guo, Y., Zheng, F., Efficacy of adenosine in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Medicine (Baltimore), 94(August (32)), 2015, e1279.
85. 85 Adjedj, J., Toh, G.G., Johnson, N.P., et al. Intracoronary adenosine: dose–response relationship with hyperaemia. J Am Coll Cardiol Interv 8 (2015), 1422–1430.
86. 86 Yetgin, T., Uitterdijk, A., Hekkert, M.L., et al. Limitation of infarct size and no-reflow by intracoronary adenosine depends critically on dose and duration. J Am Coll Cardiol Interv 8 (2015), 1990–1999.
87. 87 Werner, G.S., Lang, K., Kuehnert, H., et al. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 57 (2002), 444–451.
88. 88 Vijaylakshmi, K., Whittaker, V.J., Kunadian, B., et al. Prospective, randomized controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart 92:9 (2006), 1278–1284.
89. 89 Huang, D., Qian, I., Gee, L., et al. Restoration of coronary flow in patients with no reflow after primary coronary intervention of acute myocardial infarction (RECOVER AMI). Am Heart J 164 (2012), 394–401.
90. 90 Fu, Q., Lu, W., Huang, Y.J., et al. Verapamil reverses myocardial no-reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Cell Biochem Biophys 67:3 (2013), 911–914.
91. 91 Wang, L., Cheng, Z., Gu, Y., Peng, D., Review article: short-term effects of verapamil and diltiazem in the treatment of no reflow phenomenon: a meta-analysis of randomized controlled trials. Hindawi, 2015, 382086, 10.1155/2015/382086.
92. 92 Huang, R.I., Patel, P., Walinsky, P., et al. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. Catheter Cardiovasc Interv 68 (2006), 671–676.
93. 93 Chen, Z., Chen, X., Li, S., Huo, X., Fu, X., Dong, X., Nicorandil improves myocardial function by regulating plasma nitric oxide and enothelin-1 in coronary slow flow. Coron Artery Dis 26:March (2) (2015), 114–120.
94. 94 Ezhilan, J., Juneja, M.S., George, T., Ramkumar, S., Viswanathan, V., Badrinath, A., Prevention of no flow/slow flow phenomenon in primary PCI by nicorandil. Indian Heart J 59:3 (2007), 246–249.
95. 95 Ishii, H., Ichimiya, S., Kanashior, M., et al. Impact of single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 112 (2005), 1284–1288.
96. 96 Ono, H., Osanai, T., Ishizaka, H., et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J, 148, 2004, E15.
97. 97 Wang, H.J., Lo, P.H., Lin, J.J., et al. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv 63:2 (2004), 171–176.
98. 98 Parikh, K.H., Chag, M.C., Shah, K.J., et al. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no flow during angioplasty: a clinical scenario of ischemic preconditioning. Can J Physiol Pharmacol 85:3–4 (2007), 476–482.
99. 99 Amit, G., Cafri, C., Yaroslavtsev, S., et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J, 152, 2006 887.e9–887.e14.
100. 100 Lee, W.C., Chen, S.M., Liu, C.F., et al. Early administration of intracoronary nitroprusside compared with thrombus aspiration in myocardial perfusion for acute myocardial infarction: a 3-year clinical follow-up study. Acta Cardiol Sin 31 (2015), 373–380.
101. 101 Petronio, A.S., de Carlo, M., Ciabatti, N., et al. Left ventricular remodelling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J, 150, 2005, 1015.
102. 102 Van't Hoff, A.W., ten Berg, J., Heestermans, T., et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIMI 2): a multicentre, double-blind, randomized controlled trial. Lancet 373 (2008), 537–546.
103. 103 Gibson, C.M., Morrow, D.A., Murphy, S.A., et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol 47 (2006), 2364–2373.
104. 104 Thiele, H., Scindler, K., Friedenberger, J., et al. Intracoronary compared with intravenous bolus abciximab application in patient with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-segment myocardial infarction. Circulation 118 (2008), 49–57.
105. 105 Thiele, H., Wohrle, J., Hambrecht, R., et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomized trial. Lancet 379:9819 (2012), 923–931.
106. 106 ClinicalTrials.gov. Intracoronary cocktail injection combined with thrombus aspiration in STEMI patients treated with primary angioplasty. http://clinicaltrials.gov/ct2/show/NCT02592694.
107. 107 Prati, F., Di Vito, L., Ramazzotti, V., et al. Randomized trial of standard versus clearway-infused abciximab and thrombectomy in myocardial infarction: rationale and design of the COCKTAIL II study. J Cardiovasc Med (Hagerstown) 14:May (5) (2013), 364–371.
108. 108 Bairey Merz, N., Handberg, E.M., Shufelt, C.L., et al. A randomized, placebo controlled trial of late current inhibition (Ranolazine) in coronary micro-vascular dysfunction: impact on Angina and myocardial perfusion reserve. Eur Heart J(November), 2015, 10.1093/eurheart/ehv647.
109. 109 Murry, C.E., Jennings, R.B., Reimer, K.A., Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:5 (1986), 1124–1136.
110. 110 Zhao, Z.Q., Covera, J.S., Halkos, M.E., et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285:2 (2003), H579–H588.
111. 111 Kharbanda, R.K., Nielsen, T.T., Redington, A.N., Tanslation of remote ischemic preconditioning into clinical practice. Lancet 374:9700 (2009), 1557–1565.
112. 112 Botker, H.E., Kharbanda, R., Schmidt, M.R., et al. Remote ischemic conditioning before hospital admission, as a complement to angioplasty and effect on myocardial salvage in patients with acute myocardial infarction: a randomized trial. Lancet 375:9716 (2010), 727–734.
113. 113 Piot, C., Croisille, P., Staat, P., et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359 (2008), 473–481.
114. 114 Chakrabarti, A.K., Feeney, K., Abueg, G., et al. Rational and design of the EMBRACE STEMI Study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. Am Heart J 165 (2013), 509–514.
115. 115 Kitakaze, M., Asakura, M., Kim, J., et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomized trials. Lancet 370 (2007), 1483–1493.
116. 116 Lonborg, J., Vejlstrup, N., Kelbaek, H., et al. Exenatide rescues reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 33 (2013), 1491–1499.
117. 117 Atar, D., Petzelbauer, P., Schwitter, J., et al. Effects of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol 53:8 (2009), 720–729.
118. 118 Granger, C.B., Mahaffey, K.W., Weaver, W.D., et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA TRIAL). Circulation 108:10 (2003), 1184–1190.
119. 119 Armstrong, P.W., Granger, C.B., Adams, P.X., et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 297:1 (2007), 43–51.
120. 120 Patel, M.R., Worthely, S.G., Stebbins, A., et al. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a delayed enhancement cardiac magnetic resonance sub-study from the APEX-AMI trial. J Am Coll Cardiol Cardiovasc Imaging 3:1 (2010), 52–60.
121. + exchange inhibitor Eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardio-protective effects of eniporide in acute myocardial infarction (ESCAMI) TRIAL. J Am Coll Cardiol 38:6 (2001), 1644–1650.
122. 122 The RESTORE-SIRIO TRIAL – Clinical Trials.gov, Report. 2016, February.